-
In this issue: ACEI/ARB therapy for AS; safety alert issued for dronedarone; statins and cancer risk; nesiritide and heart failure; and FDA actions.
-
In this double-blind protocol, normal-weight (body mass index [BMI] 19.0-24.9 kg/m2) and obese (BMI 30.0-39.9 kg/m2) women with regular periods and normal ovarian ultrasound took one of two types of oral contraceptives (OCPs): either 21-day monophasic pills with 20 mcg ethinyl estradiol/100 mcg levonorgestrel or 30 mcg ethinyl estradiol/150 mcg levonorgestrel.
-
A California-based company is looking at new condom designs, including a male non-rolled silicone condom, a female silicone condom, and a silicone condom designed specifically for receptive anal intercourse.
-
Why is it so important that providers develop their skills when it comes to taking an adolescent sexual history?
-
Most adolescents who use contraception rely on combination oral contraceptive pills.
-
While only one company has received Food and Drug Administration (FDA) approval for an HIV home collection-test system that requires users to collect a blood specimen, then mail it to a laboratory for professional testing, no test kit is available to allow consumers to interpret test results at home.
-
Although there have been no documented treatment failures in the United States, untreatable gonorrhea might become a reality in this country, according to a new report from the Centers for Disease Control and Prevention (CDC).
-
Long-acting reversible contraceptive (LARC) methods the Copper T 380A intrauterine device (IUD), the levonorgestrel intrauterine system, and the contraceptive implant are the best tools clinicians have to fight against unintended pregnancies, which account for about half of U.S.
-
Trichomoniasis, caused by the parasite Trichomonas vaginalis, is the most common sexually transmitted infection (STI) in the nation, with an estimated 7.4 million men and women newly infected each year.
-
